Replies to post #734462 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

And did Dave Innes (head of PR) say last inspection to take place first half of December, and/or MHRA decision within a “few months?”

[exwannabe]

That you don’t think there are countless loopholes and ways to get around this just shows your absolute naivety regarding this whole industry.

DI could completely legally tell Senti how he thinks MHRA inspections work in general. And that is enough to trigger the signal.

[dstock07734]

You and your buddies should expect that a paper on genetic profiling analysis of tumor samples from the patients in the p3 trial could be published any time from now since the data was uploaded one year ago. It will be the paper which shows unequivocally that for the most life-threatening subtype of GBM DCVax-L (ATL-DC) has the most significant efficacy.

Dendritic Cell Vaccination in Conjunction with TLR Agonist Polarizes Interferon Immune Responses Associated with Long-term Survival in Malignant Glioma Patients
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237562

The next is something I feel really more excited about since it is related to the combo trial. Should we agree that the formal paper should be in good shape or even submitted for peer-review?

Recall this figure? What I feel confused about is that the numbers don't add up. I suppose there are three more patients on ALT-DC + adj-aPD1 group missing. I am just curious about the reason that Dr. Liau didn't mention the three patients. Given that ALT-DC + adj-aPD1 group has the OS of 57%, these three patients should be even more important.

To investigate this mechanism of immunotherapy resistance, we performed single-cell RNA-sequencing (scRNAseq) on pre- and post-vaccination tumor-infiltrating immune cells from three recurrent GBM patients enrolled in the ATL-DC + neo-aPD1 clinical trial. Additionally, we integrated our previously published and newly generated scRNAseq data encompassing 21 immunotherapy-naive and 23 neo-aPD1-treated recurrent GBM samples for comparison, representing the largest single-cell resolution analysis of the GBM immune microenvironment to date (n = 50).

819 Temporal influence of PD-1 blockade after vaccination on macrophage-driven CD8+ T cell exhaustion within the glioblastoma microenvironment
https://jitc.bmj.com/content/12/Suppl_2/A927

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
https://clinicaltrials.gov/study/NCT04201873